TransMedics Reports Positive Data from PROTECT Trial
TransMedics Group Inc. (TMDX) announced that it has received positive data from its US pivotal OCS Liver PROTECT Trial. The study is a multicenter, two-armed, prospective trial for assessing the effectiveness and safety of the OCS Liver to preserve and assess donor livers intended for transplantation. The trial studied 300 patients where 153 patients were randomized to transplantation using the OCS Liver while 147 patients were randomized to use cold storage methods.
The study met both its primary and secondary safety and effectiveness endpoints. The primary